Institute for Economic
Research on Firm and Growth
CNR-CERIS Collegio Carlo Alberto - via Real Collegio, n. 30
10024 Moncalieri (Torino) – ITALY
Tel.: +39 011 68
24 925;
fax : +39 011 68
24 966;
email:
Indirizzo e-mail protetto dal bots spam , deve abilitare Javascript per vederlo
Lili Wang
United Nations University The
Maastricht Economic and Social Research Institute
on Innovation and Technology
UNU-MERIT- Keizer Karelplein, n. 19
6211 TC Maastricht – The Netherlands
Tel.:+ 31 (0)
43-3884456
email:
Indirizzo e-mail protetto dal bots spam , deve abilitare Javascript per vederlo
Corresponding author:
Indirizzo e-mail protetto dal bots spam , deve abilitare Javascript per vederlo
Abstract: A fundamental question is
how to detect likely successful anticancer treatments based on nanotechnology.
We confront this question here by analyzing the trajectories of
nanotechnologies applied to path-breaking cancer treatments, which endeavour to
pinpoint ground-breaking and fruitful directions in nanomedicine. Results tend
to show two main technological waves of cancer treatments
by nanotechnology applications. The early technological wave in the early 2000s
was embodied in some types of chemotherapy agents with a broad
spectrum, while after 2006, the second technological wave appeared with new
nano-technological applications in both chemotherapy agents and molecular
target therapy. The present study shows new directions of nanotechnology-based
chemotherapy and -molecular cancer therapy in new treatments for breast, lung, brain and
colon cancers. A main finding of this study is the
recognition that, since the late 2000s, the sharp increase of several
technological trajectories of nanotechnologies and anticancer drugs seems to be
driven by high rates of mortality of some types of cancers (e.g. pancreatic and brain ones) in order
to find more effectiveness anticancer therapies that increase the survival of
patients. The study here also shows that worldwide leader countries in these
vital research fields and in particular the specialization of some countries in
applications of nanotechnology to treat specific cancer (e.g. Switzerland in prostate cancer, Japan in colon, China in
ovarian and Greece in pancreatic cancer). These ground-breaking technological
trajectories are paving new directions in biomedicine and generating a
revolution in clinical practice that may lead to more effective anticancer
treatments in a not-too-distant future.
Acknowledgments: This research started by the
authors in 2012 and it has been developed in 2013 while Mario Coccia was
visiting scholar at the UNU-MERIT in Maastricht. We thank Prof. Bart Verspagen for fruitful suggestions to this
paper. Mario Coccia gratefully acknowledges the CNR - National Research Council
of Italy for financial support to this research project by the short mobility
program at UNU-MERIT. Preliminary results have been presented at S.NET 4th
Annual Meeting -Fourth annual conference of the society for the study of nano
science and emerging technologies (October 22-25, 2012), University of Twente
(The Netherlands). The usual
disclaimer applies.